Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May4, 2017, Tetraphase Pharmaceuticals, Inc. announced its
financial results for the first quarter ended March31, 2017. The
full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information
contained in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
| Item9.01. | Financial Statements and Exhibits. |
(d)
Exhibits
See Exhibit Index
attached hereto.
About Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company’s TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Recent Trading Information
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) closed its last trading session down -0.54 at 7.11 with 249,688 shares trading hands.
